These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 34773903)
1. Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. Bossi P; Trama A; Bernasconi A; Grisanti S; Mohamad I; Galiana IL; Ozyar E; Franco P; Vecchio S; Bonomo P; Cirauqui BC; El-Sherify M; Ursino S; Argiris A; Pan J; Wittekindt C; D'Angelo E; Costa L; Buglione M; Johnson J; Airoldi M; Mesia R; Resteghini C; Licitra L; Orlandi E; Eur J Cancer; 2021 Dec; 159():194-204. PubMed ID: 34773903 [TBL] [Abstract][Full Text] [Related]
2. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148 [TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy. Ling F; Xu S; Li X; Sun X; Long W BMC Cancer; 2023 Feb; 23(1):169. PubMed ID: 36803974 [TBL] [Abstract][Full Text] [Related]
6. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA. Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068 [TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966 [TBL] [Abstract][Full Text] [Related]
8. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma. Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309 [TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Wei Z; Zhang Z; Luo J; Li N; Peng X J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162 [TBL] [Abstract][Full Text] [Related]
10. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653 [TBL] [Abstract][Full Text] [Related]
12. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma. Ji X; Xie C; Hu D; Fan X; Zhou Y; Zheng Y PLoS One; 2013; 8(2):e56208. PubMed ID: 23441169 [TBL] [Abstract][Full Text] [Related]
13. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up. Wu SY; Wu YH; Yang MW; Hsueh WT; Hsiao JR; Tsai ST; Chang KY; Chang JS; Yen CJ BMC Cancer; 2014 Oct; 14():787. PubMed ID: 25351202 [TBL] [Abstract][Full Text] [Related]
14. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391 [TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma. Yi J; Huang X; Gao L; Luo J; Zhang S; Wang K; Qu Y; Xiao J; Xu G Radiat Oncol; 2014 Feb; 9():56. PubMed ID: 24533569 [TBL] [Abstract][Full Text] [Related]
16. Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up. Yang Q; Zhao TT; Qiang MY; Hu L; Lv X; Ye YF; Ke LR; Yu YH; Qiu WZ; Liu GY; Huang XJ; Li WZ; Lv SH; Sun Y; Zhang LY; Pei F; Guo X; Xiang YQ; Qian CN; Huang BJ; Xia WX J Cancer; 2018; 9(17):3023-3031. PubMed ID: 30210624 [No Abstract] [Full Text] [Related]
17. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study. Chen TM; Lin KC; Yuan KS; Chang CL; Chow JM; Wu SY Radiother Oncol; 2018 Oct; 129(1):23-29. PubMed ID: 29277447 [TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051 [TBL] [Abstract][Full Text] [Related]
19. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701 [TBL] [Abstract][Full Text] [Related]
20. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy. Miao J; Xiao W; Wang L; Han F; Wu H; Deng X; Guo X; Zhao C J Cancer Res Clin Oncol; 2017 Jul; 143(7):1263-1273. PubMed ID: 28247035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]